These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines. Yıldız A; Răileanu C; Beissert T Viruses; 2024 Mar; 16(4):. PubMed ID: 38675846 [TBL] [Abstract][Full Text] [Related]
3. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Silva-Pilipich N; Beloki U; Salaberry L; Smerdou C Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543952 [TBL] [Abstract][Full Text] [Related]
5. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines. Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658 [TBL] [Abstract][Full Text] [Related]
6. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency. Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446 [TBL] [Abstract][Full Text] [Related]
7. A new generation of vaccines based on alphavirus self-amplifying RNA. Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Cañete G; Vanrell L; Smerdou C Curr Opin Virol; 2020 Oct; 44():145-153. PubMed ID: 32898764 [TBL] [Abstract][Full Text] [Related]
8. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization. Pourseif MM; Masoudi-Sobhanzadeh Y; Azari E; Parvizpour S; Barar J; Ansari R; Omidi Y Drug Discov Today; 2022 Nov; 27(11):103341. PubMed ID: 35988718 [TBL] [Abstract][Full Text] [Related]
9. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821 [TBL] [Abstract][Full Text] [Related]
10. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. Maruggi G; Ulmer JB; Rappuoli R; Yu D Curr Top Microbiol Immunol; 2022; 440():31-70. PubMed ID: 33861374 [TBL] [Abstract][Full Text] [Related]
11. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Machado BAS; Hodel KVS; Fonseca LMDS; Mascarenhas LAB; Andrade LPCDS; Rocha VPC; Soares MBP; Berglund P; Duthie MS; Reed SG; Badaró R Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835276 [TBL] [Abstract][Full Text] [Related]
12. Advancing mRNA technologies for therapies and vaccines: An African context. Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K Front Immunol; 2022; 13():1018961. PubMed ID: 36353641 [TBL] [Abstract][Full Text] [Related]
13. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884 [TBL] [Abstract][Full Text] [Related]